Filing Flows › Metagenomi Therapeutics (MGX) › Stock forecast & fair value
Metagenomi Therapeutics (MGX) stock forecast and price target
Metagenomi Therapeutics (MGX) trades at $0.71. 3 analysts' median price target is $7.00 (+887%), from $5.00 to $9.00.
Metagenomi Therapeutics' latest quarter
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for MGX stock?
The median of 3 analysts' 12-month targets is $7.00, +887% from $0.71; the range is $5.00 to $9.00. The average rating is none.
Does Metagenomi Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 0% of the quarters on record.
Is MGX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.